These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 24474234)

  • 1. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
    Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
    Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine.
    Bafutto M; Almeida JR; Leite NV; Oliveira EC; Gabriel-Neto S; Rezende-Filho J
    Arq Gastroenterol; 2011; 48(1):36-40. PubMed ID: 21537540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome.
    Andrews CN; Griffiths TA; Kaufman J; Vergnolle N; Surette MG; Rioux KP
    Aliment Pharmacol Ther; 2011 Aug; 34(3):374-83. PubMed ID: 21671966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.
    Abbas Z; Yakoob J; Jafri W; Ahmad Z; Azam Z; Usman MW; Shamim S; Islam M
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):630-9. PubMed ID: 24722560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.
    Tuteja AK; Fang JC; Al-Suqi M; Stoddard GJ; Hale DC
    Scand J Gastroenterol; 2012 Oct; 47(10):1159-64. PubMed ID: 22783919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
    Leighton MP; Lam C; Mehta S; Spiller RC
    Trials; 2013 Jan; 14():10. PubMed ID: 23302220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.
    Choi CH; Jo SY; Park HJ; Chang SK; Byeon JS; Myung SJ
    J Clin Gastroenterol; 2011 Sep; 45(8):679-83. PubMed ID: 21301358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study.
    Bustos Fernández LM; Man F; Lasa JS
    Dig Dis; 2023; 41(5):798-809. PubMed ID: 36630947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies.
    Basseri RJ; Kunkel D; Low K; Conklin JL; Pimentel M
    J Clin Gastroenterol; 2011 Oct; 45(9):790-3. PubMed ID: 21301356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).
    Lam C; Tan W; Leighton M; Hastings M; Lingaya M; Falcone Y; Zhou X; Xu L; Whorwell P; Walls AF; Zaitoun A; Montgomery A; Spiller R
    Gut; 2016 Jan; 65(1):91-9. PubMed ID: 25765462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized double-blind placebo-controlled study to evaluate the effect of long-acting mesalamine on postinfectious irritable bowel syndrome with diarrhea.
    Tuteja AK; Leung DT; Fang JC; Talley NJ; Stoddard GJ
    Neurogastroenterol Motil; 2024 Oct; 36(10):e14889. PubMed ID: 39104061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of inactivated Lactobacillus LB fermented culture medium on symptom severity: observational investigation in 297 patients with diarrhea-predominant irritable bowel syndrome.
    Tarrerias AL; Costil V; Vicari F; Létard JC; Adenis-Lamarre P; Aisène A; Batistelli D; Bonnaud G; Carpentier S; Dalbiès P; Ecuer S; Etienne J; Fantoli M; Grunberg B; Lannoy P; Lapuelle J; Margulies A; Neumeier M; Rouillon JM; Schmets L; Pingannaud MP; Coulom P; Kholer F; Canard JM
    Dig Dis; 2011; 29(6):588-91. PubMed ID: 22179215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
    J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak.
    Zanini B; Ricci C; Bandera F; Caselani F; Magni A; Laronga AM; Lanzini A;
    Am J Gastroenterol; 2012 Jun; 107(6):891-9. PubMed ID: 22525306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.
    Cindoruk M; Erkan G; Karakan T; Dursun A; Unal S
    Helicobacter; 2007 Aug; 12(4):309-16. PubMed ID: 17669103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised controlled trial of mesalazine in IBS.
    Barbara G; Cremon C; Annese V; Basilisco G; Bazzoli F; Bellini M; Benedetti A; Benini L; Bossa F; Buldrini P; Cicala M; Cuomo R; Germanà B; Molteni P; Neri M; Rodi M; Saggioro A; Scribano ML; Vecchi M; Zoli G; Corinaldesi R; Stanghellini V
    Gut; 2016 Jan; 65(1):82-90. PubMed ID: 25533646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.
    Choi CH; Kwon JG; Kim SK; Myung SJ; Park KS; Sohn CI; Rhee PL; Lee KJ; Lee OY; Jung HK; Jee SR; Jeen YT; Choi MG; Choi SC; Huh KC; Park H
    Neurogastroenterol Motil; 2015 May; 27(5):705-16. PubMed ID: 25809913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.